Head-to-head · WeighScore
Obu Health vs Zealthy
The verdict
Obu Health takes it — 59.9/100 to 46.7/100.
Obu Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Obu Health is a Las Vegas-based multi-product telehealth platform offering compounded semaglutide from $190/month and compounded tirzepatide from $239/month, plus NAD+ and sermorelin add-ons.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Obu Health | Zealthy |
|---|---|---|
| WeighScore | 59.9/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #332 | #496 |
| Semaglutide | $190/mo (starting dose, plus a separate fee, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $239/mo (starting dose, plus a separate fee, compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #332 · C
Strengths
- LegitScript-certified with publicly displayed ID (44206977)
- Two named 503A compounding-pharmacy partners (Manifest Pharmacy SC + RX Compounding Store FL) — transparency above category baseline
- Lower advertised semaglutide starting price ($190) than most multi-product peer platforms
- Multi-product offering (GLP-1s + NAD+ + sermorelin + generic ED + birth control) for single-platform users
- 24-hour US board-certified physician response window
Where it loses points
- Per-dose pricing tiers not transparently published on product pages — only 'starting from' prices visible
- No explicit state-coverage list disclosed; FAQ confirms restrictions exist 'based on state' without enumeration
- Medical director not named publicly
- No published consultation fee disclosure — unclear whether physician visit is included in medication price
- All sales final per FAQ ('Federal and State law do not allow medication returns')
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.